Earnings Release • Aug 4, 2017
Earnings Release
Open in ViewerOpens in native device viewer
Financial
Strategic - operational
Hans Stols, CEO of Fagron: "Fagron can look back on a strong first half of 2017. Our core businesses in Europe, South America and North America achieved good growth in both turnover and profit. The sterile compounding operations in the United States achieved turnover growth of more than 22%, a clear acceleration compared to previous half-years. The costs of the company were well controlled resulting in a profitability that increased faster than turnover.
We also made important operational progress in the past six months. We launched many innovative products and concepts on the market to meet the growing demand for individualised patient care. In South America and in Europe, this included the introduction of TrichoConcept® (a patented total solution for alopecia), Pigmerise® MD (a treatment for vitiligo) and FagronLab® (advanced equipment for pharmaceutical compounding), while in the United States we brought our Lets Gel Kit® (an anaesthetic gel) to the market. We are also pleased with the opening of a new compounding facility in Hoogeveen (the Netherlands) during the first half of 2017. This new facility is an important element of the strategy of strengthening our position in hospitals. In addition, we completed the acquisition of Kemig, a leading supplier of pharmaceutical raw materials and packaging materials to pharmacies and wholesalers in Croatia and Bosnia and Herzegovina, early August 2017.
1 EBITDA before non-recurrent result.
After refinancing the company last year, we focused on further decreasing our leverage in the first half, as a result of which we are operating comfortably within the covenants for our loans, and have created a solid financial position. We subsequently repaid our bond loan of € 225 million just after the close of the first halfyear."
| Income statement (x € 1,000) | H1 2017 | H1 2016 | Δ |
|---|---|---|---|
| Net turnover | 221,725 | 210,237 | +5.5% |
| Gross margin | 138,602 | 133,488 | +3.8% |
| As % of net turnover | 62.5% | 63.5% | |
| Operating costs | 90,491 | 87,917 | +2.9% |
| As % of net turnover | 40.8% | 41.8% | |
| EBITDA before non-recurrent result | 48,111 | 45,571 | +5.6% |
| As % of net turnover | 21.7% | 21.7% | |
| Non-recurrent result | -927 | -1,674 | -44.6% |
| EBITDA | 47,183 | 43,897 | +7.5% |
| As % of net turnover | 21.3% | 20.9% | |
| Depreciation and amortisation | 8,748 | 10,036 | -12.8% |
| EBIT | 38,435 | 33,861 | +13.5% |
| As % of net turnover | 17.3% | 16.1% | |
| Financial result, excluding revaluation of financial derivatives | -13,298 | -11,677 | -13.9% |
| Revaluation of financial derivatives | 713 | 1,296 | -45.0% |
| Profit before taxes | 25,850 | 23,480 | +10.1% |
| Taxes | -4,796 | -6,899 | -30.5% |
| Net profit from continued operations | 21,054 | 16,582 | +27.0% |
| Result from discontinued operations | - | -536 | -100% |
| Recurring net profit2 | 20,879 | 13,496 | +54.7% |
| Net profit per share (€) | 0.29 | 0.44 | -34.1% |
| Recurring net profit per share (€) | 0.29 | 0.37 | -21.6% |
| Average number of shares | 71,740,277 | 36,937,855 | +94.2% |
2 Recurrent net profit is defined as the profit before non-recurring items and revaluation of financial derivatives, corrected for taxes.
| Balance sheet (x € 1,000) | 30-06-2017 | 31-12-2016 |
|---|---|---|
| Intangible fixed assets | 349,854 | 371,006 |
| Property, plant and equipment | 69,626 | 72,879 |
| Deferred tax assets | 10,765 | 9,698 |
| Financial assets | 2,074 | 2,123 |
| Operational working capital | 30,895 | 39,770 |
| Other working capital | -33,283 | -29,972 |
| Equity | 164,712 | 152,875 |
| Provisions and pension obligations | 19,864 | 18,456 |
| Financial instruments | 26 | 8,530 |
| Deferred tax liabilities | 161 | 236 |
| Net financial debt | 245,168 | 285,408 |
The consolidated turnover amounts to € 221.7 million, an increase of 5.5% (0.7% at constant exchange rates) compared to the first half of 2016. Organic growth amounts to 6.0% (1.2% at constant exchange rates). The turnover development per segment is set out in more detail in the section 'Key figures per segment'.
| (x € 1,000) | H1 2017 | H1 2016 | Total growth |
Total growth CER |
Org. growth |
Org. growth CER |
|---|---|---|---|---|---|---|
| Fagron | 218,265 | 205,678 | 6.1% | 1.3% | 6.6% | 1.8% |
| HL Technology | 3,461 | 4,559 | -24.1% | -25.4% | -24.1% | -25.4% |
| Fagron Group | 221,725 | 210,237 | 5.5% | 0.7% | 6.0% | 1.2% |
CER = Constant Exchange Rates
The gross margin increases by € 5.1 million or 3.8% to € 138.6 million. As a percentage of turnover, the gross margin declines by 100 base points to 62.5% compared to the same period in the previous year, but increased by 30 base points compared to the second half of 2016.
Operating costs as a percentage of turnover decrease by 100 base points to 40.8%.
The EBITDA before non-recurrent result increases by € 2.5 million or 5.6% to € 48.1 million. With the exception of HL Technology, the operations of Fagron in North America, South America and Europe contributed to the increase in the EBITDA before the non-recurrent result.
The non-recurrent result amounts to -€ 0.9 million, a change of 44.6% compared to -€ 1.7 million in the first half of 2016.
The EBITDA increases by € 3.3 million or 7.5% to 47.2 million. The EBITDA as a percentage of turnover increases by 40 base points to 21.3%.
Depreciation and amortisation amounts to € 8.7 million, compared to € 10.0 million in the first half of 2016. The decline was mainly due to the accelerated depreciation of assets in 2016 at Freedom Pharmaceuticals and Fagron Academy in the United States and HL Technology in Switzerland.
The EBIT amounts to € 38.4 million, an increase of 13.5% compared to € 33.9 million in the first half of 2016. The EBIT as a percentage of turnover increases by 120 base points to 17.3%.
Excluding the revaluation of the financial derivatives, the financial result amounts to -€ 13.3 million, a decrease of 13.9% compared to the first half of 2016.
The revaluation of the financial derivatives amounts to € 0.7 million. These financial derivatives do not qualify for hedge accounting according to IAS 39.
The effective tax rate as a percentage of the profit before taxes is 18.6% in the first half of 2017, compared to 29.4% in the first half of 2016.
In the first half of 2017, the net profit from continued operations amounts to € 21.1 million, an increase of 27.0% compared to € 16.6 million in the first half of 2016.
The main changes at balance-sheet level can be summarised as follows.
The intangible non-current assets decrease by € 21.2 million in the first half of 2017. The decline in the intangible non-current assets was mainly due to the appreciation of the Brazilian real and the US dollar against the euro, and the sale of the compounding facility in Paris (France).
Property, plant and equipment decrease by € 3.3 million in the first half of 2017. This decrease was mainly due to the appreciation of the Brazilian real and the US dollar against the euro.
Operational working capital decreases by 22.3% or € 8.9 million to € 30.9 million in the first half of 2017. The operational working capital as a percentage of turnover was 7.1%.
The net financial debt decreases by € 40.2 million to € 245.2 million in the first half of 2017. On 30 June 2017, the net financial debt/REBITDA ratio is 2.66, which is comfortably below the level of 3.25 set in the Revolving
Credit Facility and the Note Purchase Agreement. The following table summarises the development in the net financial debt in the first half of 2017.
| (x € 1,000) | |
|---|---|
| Net financial debt at 31 December 2016 | -285,408 |
| Operating cash flow | 49,501 |
| Investment activities | -103 |
| Net interest paid | -12,669 |
| Exchange rate differences | 3,511 |
| Net financial debt at 30 June 2017 | -245,168 |
The net operational capex amounts to € 5.1 million (2.3% of turnover) in the first half of 2017. Capex consisted primarily of investments in new compounding facilities in the United States, the Netherlands and South Africa, improvements to facilities in Brazil, automation of logistics processes, and software implementations. The compounding facilities stated have been operational since March 2017 (Wichita, US) and June 2017 (Hoogeveen, the Netherlands and Johannesburg, South Africa).
| (x € 1,000) | H1 2017 | H1 2016 | Change |
|---|---|---|---|
| Turnover | 218,265 | 205,678 | 6.1% |
| REBITDA3 | 48,230 | 44,706 | 7.9% |
| REBITDA margin | 22.1% | 21.7% |
Fagron's turnover increases 6.1% in the first half of 2017 (1.3% at constant exchange rates) to € 218.3 million. The organic turnover growth is 6.6% (1.8% at constant exchange rates). REBITDA increases 7.9% to € 48.2 million. As a percentage of turnover, REBITDA increases by 40 base points to 22.1%.
The following table summarises the turnover development and currency effects for Fagron (excluding HL Technology) in the first half of 2017.
| (x € 1,000) | Impact |
|---|---|
| Turnover from continued operations in H1 2016 | |
| Development Europe4 | +3,050 |
| Development South America | -924 |
| Development North America | +600 |
| Currency effect BRL/EUR | +8,098 |
| Currency effect USD/EUR | +1,182 |
| Currency effect other | +580 |
| Turnover from continued operations in H1 2017 | 218,265 |
| Fagron Europe5 | |||
|---|---|---|---|
| (x € 1,000) | H1 2017 | H1 2016 | Change |
| Turnover | 128,886 | 125,346 | 2.8% |
| REBITDA6 | 32,724 | 30,920 | 5.8% |
| REBITDA margin | 25.4% | 24.7% |
Turnover for the segment Europe increases by 2.8% in the first half of 2017 (2.4% at constant exchange rates) to € 128.9 million. The organic turnover growth is 3.7% (3.3% at constant exchange rates). REBITDA increases 5.8% to € 32.7 million. As a percentage of turnover, REBITDA increases by 70 base points to 25.4%.
On 29 June 2017, Fagron opened a new compounding facility in Hoogeveen (the Netherlands). This facility specialises in the production of prefilled (sterile) glass syringes with a long shelf life for the hospital market. The syringes have unique features, including colour coding, Tall Man lettering and 2D coding for dispensing registration, which contribute to optimal medication safety. This new facility is an important element in Fagron's strategy of strengthening its position in hospitals.
Fagron completed the sale of a compounding facility in Paris (France) in June 2017. The Board of Directors decided to divest because the compounding facility in France was barely profitable and had limited growth potential. The compounding facility realised turnover of € 9.7 million in 2016. The operations and results of the compounding facility in Paris were deconsolidated on 1 July 2017.
Fagron completed the acquisition of Kemig at the beginning of August 2017. Kemig is a leading supplier of pharmaceutical raw materials and packaging materials to pharmacies and wholesalers in Croatia and Bosnia and Herzegovina. Located in Zagreb (Croatia), Kemig realised turnover of approximately € 4 million in 2016, with an EBITDA margin that is below the average of Fagron Europe. Kemig is consolidated with effect from 1 July 2017.
4 This excludes the negative effect of € 1 million due to the sale of a small compounding facility in Marseille (France) in 2016.
5 The Europe segment consists of the operations of Fagron in Europe, South Africa and Australia.
6 EBITDA before non-recurrent result.
| (x € 1,000) | H1 2017 | H1 2016 | Change |
|---|---|---|---|
| Turnover | 49,498 | 42,234 | 17.2% |
| REBITDA7 | 10,054 | 8,741 | 15.0% |
| REBITDA margin | 20.3% | 20.7% |
The turnover of the segment South America increases by 17.2% in the first half of 2017 (-2.2% at constant exchange rates) to € 49.5 million. REBITDA increases 15.0% to € 10.1 million. REBITDA as a percentage of turnover decreases by 40 base points to 20.3%.
The majority of Fagron Brazil's purchases are in US dollars, which led to lower purchase prices as a result of the current appreciation of the Brazilian real against the US dollar (+14.2% over the period). This positive currency effect was fully passed on to customers, as usual. Fagron Brazil was able to further strengthen its market leadership in the first half of 2017 by achieving significant volume growth.
| Fagron North America | |||
|---|---|---|---|
| (x € 1,000) | H1 2017 | H1 2016 | Change |
| Turnover | 39,880 | 38,098 | 4.7% |
| REBITDA8 | 5,452 | 5,045 | 8.1% |
| REBITDA margin | 13.7% | 13.2% |
The turnover of the segment North America increases by 4.7% in the first half of 2017 (1.6% at constant exchange rates) to € 39.9 million. REBITDA increases 8.1% to € 5.5 million. REBITDA as a percentage of turnover increases 50 base points to 13.7% compared to the first half of 2016.
Fagron's sterile compounding activities in the United States achieve turnover growth of 22.7% in the first half of 2017 (19.1% at constant exchange rates). The 503B compounding facility in Wichita, in operation since March 2017, is performing in line with expectations of the company. This facility has currently obtained licences from 46 states, including the important states of New York, Florida and Texas.
The sale of pharmaceutical raw materials and compounding concepts declines by 26.7% in the first half of 2017 (-28.8% at constant exchange rates) compared to the first half of 2016. However the second quarter of 2017 is the second consecutive quarter in which we are seeing an improvement.
| HL Technology | |||
|---|---|---|---|
| (x € 1,000) | H1 2017 | H1 2016 | Change |
| Turnover | 3,461 | 4,559 | -24.1% |
| REBITDA9 | -119 | 865 | -113.8% |
| REBITDA margin | -3.4% | 19.0% |
7 EBITDA before non-recurrent result.
8 EBITDA before non-recurrent result.
9 EBITDA before non-recurrent result.
The turnover of HL Technology decreases by 24.1% in the first half of 2017 (-25.4% at constant exchange rates) to € 3.5 million. REBITDA decreases by € 1.0 million to -€ 0.1 million.
Fagron reviewed the strategic options for HL Technology in the past period. Further announcements will be made in due course.
Hans Stols (CEO) and Karin de Jong (CFO) will provide further details on the results for the first half of 2017 today in a conference call. The conference call begins at 09:30 CET. From 5 to 10 minutes in advance, you will be able to call in using the numbers and confirmation code below:
Netherlands: +31 (0)20 721 9251 Belgium/Europe: +32 (0)2 404 0659 United States: +1 719 457 2086 United Kingdom: +44 (0)330 336 9105 Confirmation code: 8507613
The presentation will be available from 09:00 CET at http://investors.fagron.com.
The conference call will be available to listen to or download from Fagron's corporate website as of 7 August (http://investors.fagron.com/).
12 October Trading update, third quarter 2017
The results and trading updates will be published at 07:00 CET.
In the event of differences between the English translation and the Dutch original of this press release, the latter shall prevail.
Constantijn van Rietschoten Chief Communications Officer Tel. +31 6 53 69 15 85 [email protected] investors.fagron.com
Fagron is a leading global company active in pharmaceutical compounding and focused on delivering tailored pharmaceutical care to hospitals, pharmacies, clinics and patients in 34 countries around the world.
The Belgian company Fagron NV is located in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is in Rotterdam.
Certain statements in this press release could be considered to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Fagron consequently cannot provide any guarantees that such forward-looking statements will in fact materialise, and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.